Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on October 2, 2019, regarding events occurring on September 30, 2019. The filing details the completion of a strategic acquisition and the entry into multiple material definitive agreements with Razor Genomics Inc. ("Razor") and Encore Clinical, Inc. ("Encore").
Key Financial Metrics and Transaction Details
- Acquisition Cost: OncoCyte paid $10 million in cash to purchase 1,329,870 shares of Razor's Series A Convertible Preferred Stock.
- Milestone Payment: OncoCyte paid Encore $1 million in cash as a milestone payment for receiving a preliminary positive coverage decision from the Centers for Medicare and Medicaid Services (CMS) for Razor's lung cancer prognostic assay.
- Operating Costs: OncoCyte will pay Encore a quarterly fee for the use of Razor's CLIA laboratory in Brisbane, California, covering operations, maintenance, and staffing.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for OncoCyte. It focuses solely on the transaction details.
Material Changes and Agreements
The filing reports the following material changes and new agreements effective September 30, 2019:
- Equity Acquisition: Completion of the purchase of Razor's Series A Convertible Preferred Stock.
- Future Purchase Rights: Execution of Minority Holder Stock Purchase Agreements granting OncoCyte the right to purchase remaining Razor common stock held by minority shareholders in the future.
- Commercialization Rights: Entry into a Sublicense and Distribution Agreement granting OncoCyte the right to commercialize the Razor Assay under sublicensed patents.
- Development and Consulting: Execution of a Development Agreement and a Consulting Agreement with Encore.
- Laboratory Access: Amendment to a Laboratory Services Agreement allowing OncoCyte to use Razor's CLIA laboratory until September 29, 2021, with options to extend or terminate.
Outlook, Risks, and Management Commentary
Management highlights the strategic importance of the Razor Assay, which is designed to identify lung cancer patients at high risk for recurrence to enable timely chemotherapy treatment. The filing includes extensive forward-looking statements regarding the transaction's closing, clinical trial results, and reimbursement approvals.
Key Risks and Contingencies:
- Uncertainty regarding the ability to close the full transaction in a timely manner or at all.
- Risks inherent in the development and commercialization of the Razor Assay.
- Uncertainty in clinical trial results and potential failure to obtain Medicare or private insurer reimbursement.
- The need to obtain future capital to complete the acquisition and fund operations.
- Maintenance of intellectual property rights.
Investor Verification Checklist
- Verify the status of the preliminary positive coverage decision from CMS for the Razor Assay.
- Review the terms of the Minority Holder Stock Purchase Agreements to understand the timeline and conditions for acquiring the remaining Razor common stock.
- Assess OncoCyte's current cash position and ability to fund the $10 million acquisition, the $1 million milestone, and future capital needs without raising additional equity or debt.
- Examine the specific quarterly fee structure for the Laboratory Services Agreement to understand ongoing operational costs.
- Review the full text of the Subscription and Stock Purchase Agreement and Sublicense Agreement filed as exhibits to this report.